Hillevax


HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Their initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infecti... Read more

Industries

Employees

11-50

Links


Org chart

Rob Hershberg
CEO, President & Chair
Collapse
Shane Maltbie
Chief Financial Officer
Astrid Borkowski
Chief Medical Officer
Paul Bavier
General Counsel, Secretary & Chief Administrative Officer
Anju Chatterji
Chief Technology Officer
Chao Huang
Senior Director
Lynn Ferrucci
Vice President Human Resources
John Markels
Strategic Advisor

Board & advisors

Gary Dubin
Director